Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-κB in HCT116 colon cancer cells

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 41-47

  Lee, Hye Ran ^a   Cheong, Hee Jeong ^b   Kim, Sook Ja ^b   Lee, Nam Su ^b   Park, Hee Sook ^b   Won, Jong ho ^b  

^a Inje University College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; Colon cancer cells; NF B; Sulindac

Indexed keywords

ARSENIC TRIOXIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; SULINDAC; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; ORGANOARSENIC DERIVATIVE; OXIDE;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; STAINING; WESTERN BLOTTING; ACTIVE TRANSPORT; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CASPASE 3; CASPASE 8; CELL PROLIFERATION; DRUG SYNERGISM; HCT116 CELLS; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; OXIDES; PHOSPHORYLATION; SULINDAC;

EID: 49849086294     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.41     Document Type: Article

References (43)

1. Miller WH, Schipper HM, Lee JS, Singer J and Waxman S: Mechanism of action of arsenic trioxide. Cancer Res 62: 3893-3909, 2002.
2. Niu C, Yan H, Sun HP, Liu JX, Gu BW, Su XY, Cao Q, Waxman S, Chen Z, Chen S, Shen ZX and Wang ZY: Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide. Blood 92 (Suppl 1): 678a, 1998.
3. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang Y, Chen KQ, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
4. De The H, Chomienne C, Lanotte M, Degos L and Dejean A: The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347: 558-561, 1990.
5. Kakizuka A, Miller, Umesono K, Warrel RP, Frankel SR, Murty VV, Dmitrovsky E and Evans R: Chromosomal translocation t(15;17) in acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 6632-6721, 1991.
6. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
7. 3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 116: 555-563, 2002.
8. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY and Kim BK: Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 18: 249-255, 2001.
9. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A and Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12: 1383-1391, 1998.
10. Jing Y, Wang L, Xia L, Chen GO, Chen Z, Miller WH and Waxman S: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia in vitro and in vivo. Blood 97: 264-269, 2001.
11. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O and de The H: Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 93: 278-283, 1999.
12. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam K and Wong CY: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 91: 173-179, 2001.
13. Perkins C, Kim CN, Fang G and Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014-1022, 2000.
14. Woo SH, Park IC, Park MJ, Lee SJ, Chun YJ, Lee SI, Hong SI and Rhee CH: Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 21: 57-63, 2002.
15. Berman KS, Verma UN, Harburg G, Minna J, Cobb MH and Gaynor RB: Sulindac enhances tumor necrosis factor-α mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin Cancer Res 8: 354-360, 2002.
16. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V and Reddy BS: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55: 1464-1472, 1995.
17. Yamamato Y and Gaynor R: Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Investig 107: 135-142, 2001.
18. Han S, Kim K, Hahm E, Park C, Kimbler BF, Lee SJ, Lee S, Kim WS, Jung CW, Park K, Kim J, Yoon S, Lee J and Park S: Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94: 695-707, 2005.
19. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommmert K and Dorken B: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102: 1028-1034, 2003.
20. 3) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 24: 3339-3347, 2005.
21. Jin H, Yoon S, Seo S, Lee H, Woo S, Yoo D, Lee S, Choe T, An S, Kwon T, Kim J, Park M, Hong S, Park I and Rhee C: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of surviving. Biochem Pharma 72: 1228-1236, 2006.
22. Park WH, Cho YH, Jung CW, Park JO, Kim K, Im YH, Lee MH, Kang WK and Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophy Res Commun 300: 230-235, 2003.
23. Baumgartner M, Sturlan S, Roth E, Wessner B and Bachleitner-Hoffmann T: Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 112: 707-712, 2004.
24. 3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 23: 3945-3952, 2004.
25. Lavagna C, Burguad J, Soldato PD and Rampal P: Antiproliferative effects of nitrosulindac on human colon adenocarcinoma cell lines. Biochem Biophy Res Commun 284: 808-816, 2001.
26. Sun BC, Zhao XL, Zhang SW, Liu YX, Wang L and Wang X: Sulindac induces apoptosis and protects against colon carcinoma in mice. World J Gastroenterol 11: 2822-2826, 2005.
27. Duggan DE: Sulindac: therapeutic implications of the prodrug/ pharmacophore equilibrium. Drug Metab Rev 12: 325-337, 1981.
28. He TC, Chan TA, Vogelstein B and Kinzler KW: PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345, 1999.
29. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60: 3338-3342, 2000.
30. Jiang TT, Brown SL and Kim JH: Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J Exp Clin 23: 259-262, 1999.
31. Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Kim SJ, Youn MJ, So HS and Park R: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspases cascade and mitochondrial dysfunction. Int J Oncol 28: 1401-1408, 2006.
32. Li X, Ding X and Adrian TE: Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 27: 174-179, 2003.
33. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T and Nicot C: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98: 3762-3769, 2001.
34. Soignet S, Maslak P, Wang ZG, Jhanwar S, Calleja E, Darnashti J, Corso D, De Blasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
35. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S and Anderson KC: Arsenic trioxide inhibits growth of human multiple myeloma cells in the one marrow microenvironment. Mol Cancer Ther 1: 851-860, 2002.
36. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999.
37. Huang XJ, Wiernik PH, Klein RS and Gallagher RE: Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 16: 58-64, 1999.
38. 1 phase accumulation by arsenic trioxide in an adult T-cell leukemia cell line, MT-1. Blood 94 (Suppl 1): 263b, 1999.
39. Shishodia A and Aggarwal B: Nuclear factor-κB activation: a question of life or death. J Biochem Mol Biol 35: 28-40, 2002.
40. Mercurio F and Manning AM: Multiple signals converging on NF-κB. Curr Opin Cell Biol 11: 226-232, 1999.
41. Chu Z, McKinsey T, Liu L, Gentry J, Malim M and Ballard D: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA 94: 10057-10062, 1997.
42. Park M, Lee J, Gwak H, Park C, Lee H, Woo SH, Jin H, Han C, An S, Lee S, Chung HY, Park I, Hong S and Rhee CH: Arsenic trioxide inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-κB and reactive oxygen species. J Cell Biochem 95: 955-969, 2005.
43. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute cooperative research and development studies. Oncologist 6: 22-28, 2001.